TY - JOUR
T1 - Association of self-identified race and genetic ancestry with the immunogenomic landscape of primary prostate cancer
AU - Vidotto, Thiago
AU - Imada, Eddie L.
AU - Faisal, Farzana
AU - Murali, Sanjana
AU - Mendes, Adrianna A.
AU - Kaur, Harsimar
AU - Zheng, Siqun
AU - Xu, Jianfeng
AU - Schaeffer, Edward M.
AU - Isaacs, William B.
AU - Sfanos, Karen S.
AU - Marchionni, Luigi
AU - Lotan, Tamara L.
N1 - Funding Information:
This research was supported in part by 2 Health Disparity Research Awards from the CDMRP-PCRP (W81XWH-17-1-0286 to KSS andTLL; W81XWH-19-1-0292 to TLL). Additional funding and resources were provided by the Schaufeld Program for Prostate Cancer in Black Men and the NCI Cancer Center Support grants 5P30CA006973-52 to TLL and R01 CA200859 to LM.
Publisher Copyright:
© 2023, Vidotto et al.
PY - 2023/2/8
Y1 - 2023/2/8
N2 - The genomic and immune landscapes of prostate cancer differ by self-identified race. However, few studies have examined the genome-wide copy number landscape and immune content of matched cohorts with genetic ancestry data and clinical outcomes. Here, we assessed prostate cancer somatic copy number alterations (sCNA) and tumor immune content of a grade-matched, surgically treated cohort of 145 self-identified Black (BL) and 145 self-identified White (WH) patients with genetic ancestry estimation. A generalized linear model adjusted with age, preoperative prostate-specific antigen (PSA), and Gleason Grade Group and filtered for germline copy number variations (gCNV) identified 143 loci where copy number varied significantly by percent African ancestry, clustering on chromosomes 6p, 10q, 11p, 12p, and 17p. Multivariable Cox regression models adjusted for age, preoperative PSA levels, and Gleason Grade Group revealed that chromosome 8q gains (including MYC) were significantly associated with biochemical recurrence and metastasis, independent of genetic ancestry. Finally, Treg density in BL and WH patients was significantly correlated with percent genome altered, and these findings were validated in the TCGA cohort. Taken together, our findings identify specific sCNA linked to genetic ancestry and outcome in primary prostate cancer and demonstrate that Treg infiltration varies by global sCNA burden in primary disease.
AB - The genomic and immune landscapes of prostate cancer differ by self-identified race. However, few studies have examined the genome-wide copy number landscape and immune content of matched cohorts with genetic ancestry data and clinical outcomes. Here, we assessed prostate cancer somatic copy number alterations (sCNA) and tumor immune content of a grade-matched, surgically treated cohort of 145 self-identified Black (BL) and 145 self-identified White (WH) patients with genetic ancestry estimation. A generalized linear model adjusted with age, preoperative prostate-specific antigen (PSA), and Gleason Grade Group and filtered for germline copy number variations (gCNV) identified 143 loci where copy number varied significantly by percent African ancestry, clustering on chromosomes 6p, 10q, 11p, 12p, and 17p. Multivariable Cox regression models adjusted for age, preoperative PSA levels, and Gleason Grade Group revealed that chromosome 8q gains (including MYC) were significantly associated with biochemical recurrence and metastasis, independent of genetic ancestry. Finally, Treg density in BL and WH patients was significantly correlated with percent genome altered, and these findings were validated in the TCGA cohort. Taken together, our findings identify specific sCNA linked to genetic ancestry and outcome in primary prostate cancer and demonstrate that Treg infiltration varies by global sCNA burden in primary disease.
UR - http://www.scopus.com/inward/record.url?scp=85147625502&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85147625502&partnerID=8YFLogxK
U2 - 10.1172/jci.insight.162409
DO - 10.1172/jci.insight.162409
M3 - Article
C2 - 36752203
AN - SCOPUS:85147625502
SN - 2379-3708
VL - 8
JO - JCI Insight
JF - JCI Insight
IS - 3
M1 - e162409
ER -